Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.165
Sell
RSI(14)
42.720
Neutral
STOCH(KDJ)(9,3,3)
25.610
Buy
ATR(14)
0.552
Low Volatility
CCI(14)
-79.774
Neutral
Williams %R
61.127
Sell
TRIX(12,20)
-0.781
Sell
StochRSI(14)
100.000
Buy
Alpha Cognition Inc
ACOG5.100USD
+0.600+13.33%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
82.88MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Alpha Cognition Inc
Currency: USD Updated: 2026-02-06Key Insights
Alpha Cognition Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 100 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alpha Cognition Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Alpha Cognition Inc Highlights
StrengthsRisks
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -3.73, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.40M shares, increasing 19.21% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 61.60K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
18.000
Target Price
+300.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Alpha Cognition Inc is 7.09, ranking 131 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
8.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.06
Operational Efficiency
5.70
Growth Potential
6.82
Shareholder Returns
7.09
Alpha Cognition Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Alpha Cognition Inc is 6.06, ranking 135 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -3.73, which is -58.92% below the recent high of -1.53 and -122.19% above the recent low of -8.30.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 100/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Alpha Cognition Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 18.00, with a high of 18.00 and a low of 18.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
18.000
Target Price
+300.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Alpha Cognition Inc
ACOG
1
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Alpha Cognition Inc is 6.88, ranking 99 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 6.40 and the support level at 4.15, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.932
Buy
MA10
5.184
Sell
MA20
5.551
Sell
MA50
5.815
Sell
MA100
6.331
Sell
MA200
7.588
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Alpha Cognition Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 33.08%, representing a quarter-over-quarter decrease of 2.30%. The largest institutional shareholder is Paul Tudor Jones, holding a total of 61.60K shares, representing 0.28% of shares outstanding, with 35.17% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alpha Cognition Inc is 2.68, ranking 123 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.60. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.60
VaR
--
240-Day Maximum Drawdown
+59.96%
240-Day Volatility
+107.20%
Return
Best Daily Return
60 days
+10.10%
120 days
+13.21%
5 years
--
Worst Daily Return
60 days
-10.36%
120 days
-19.92%
5 years
--
Sharpe Ratio
60 days
-0.98
120 days
-1.88
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+59.96%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.24
3 years
--
5 years
--
Skewness
240 days
+0.75
3 years
+2.69
5 years
--
Volatility
Realised Volatility
240 days
+107.20%
5 years
--
Standardised True Range
240 days
+12.36%
5 years
--
Downside Risk-Adjusted Return
120 days
-264.06%
240 days
-264.06%
Maximum Daily Upside Volatility
60 days
+67.89%
Maximum Daily Downside Volatility
60 days
+49.31%
Liquidity
Average Turnover Rate
60 days
+0.39%
120 days
+0.54%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Pharmaceuticals
Alpha Cognition Inc
ACOG
6.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
